Fibronectin induces EMT in prostate cancer cells with no or low levels of CD82, while it promotes MET, the reverse process of EMT, in the cells with high CD82 levels, indicating differential effects of fibronectin on epithelial-mesenchymal plasticity depending on CD82 expression levels. The gene discussed is CD82; the disease is Familial prostate cancer.